Forest Laboratories, Inc. (NYSE:FRX) today announced that Robert Bailey was appointed Senior Vice President, Chief Legal Officer General Counsel. In this role, Bailey will be responsible to manage the legal affairs of the Company, and will also serve as the company’s Corporate Secretary. Bailey will report to Brent Saunders, Chief Executive Officer and President, and serve as a member of the Forest Executive Team. Bailey succeeds Herschel Weinstein, who served as outside legal counsel to Forest for many years and as Forest’s General Counsel since 2006 and who will serve as a senior legal advisor to the Company on a transitional basis. Commenting on the appointment of Mr. Bailey to this new position, Brent Saunders, CEO and President said, “Bob brings to Forest extensive experience in mergers, acquisitions and licensing along with expertise in complex litigation, corporate governance and securities law. Bob is a good business leader and executive with a track record as an outstanding business partner, an excellent advisor to management and the board of directors and a strong legal team leader. These are essential skills for Forest as we embark on a plan to rejuvenate the company to drive sustained growth.” “I thank Herschel for his many years of service to Forest Laboratories and I appreciate his willingness to serve in an advisory capacity during the transition. During his 30 year association with Forest, Herschel provided excellent counsel to senior management, developed and grew the internal legal function and helped the company negotiate deals necessary to execute our next 9 strategy,” said Saunders. Bailey most recently served from 2007 to 2013 as Executive Vice President, Law, Policy and Communications at Bausch + Lomb. Before joining Bausch + Lomb in 1994, Bailey was an attorney at Nixon Peabody (formerly Nixon Hargrave Devans & Doyle). Bailey received his law degree from the University of Minnesota, and his undergraduate degree from St. Olaf College in Northfield, MN.
About Forest LaboratoriesForest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com. Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.